Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants


The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Tumour-derived MYC mutants show enhanced oncogenicity in vivo.
Figure 2: Wild-type and mutant MYC show apoptotic, but not proliferative, differences in vivo.
Figure 3: Impaired Bim induction contributes to the increased oncogenicity of mutant MYC alleles.
Figure 4: Impact of mutations in MYC on p53 tumour suppressor action and Bim induction in human Burkitt's lymphomas.

Similar content being viewed by others


  1. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 1–11 (1999)

    Article  CAS  Google Scholar 

  2. Cole, M. D. Activation of the c-myc oncogene. Basic Life Sci. 38, 399–406 (1986)

    CAS  PubMed  Google Scholar 

  3. Spencer, C. A. & Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56, 1–48 (1991)

    Article  CAS  Google Scholar 

  4. Dalla-Favera, R. et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824–7827 (1982)

    Article  ADS  CAS  Google Scholar 

  5. Davis, M., Malcolm, S. & Rabbitts, T. H. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature 308, 286–288 (1984)

    Article  ADS  CAS  Google Scholar 

  6. Bhatia, K. et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet. 5, 56–61 (1993)

    Article  CAS  Google Scholar 

  7. Albert, T., Urlbauer, B., Kohlhuber, F., Hammersen, B. & Eick, D. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 9, 759–763 (1994)

    CAS  PubMed  Google Scholar 

  8. Clark, H. M. et al. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res. 54, 3383–3386 (1994)

    CAS  PubMed  Google Scholar 

  9. Henriksson, M., Bakardjiev, A., Klein, G. & Luscher, B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8, 3199–3209 (1993)

    CAS  PubMed  Google Scholar 

  10. Hoang, A. T. et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell. Biol. 15, 4031–4042 (1995)

    Article  CAS  Google Scholar 

  11. Westaway, D., Payne, G. & Varmus, H. E. Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors. Proc. Natl Acad. Sci. USA 81, 843–847 (1984)

    Article  ADS  CAS  Google Scholar 

  12. Salghetti, S. E., Kim, S. Y. & Tansey, W. P. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 18, 717–726 (1999)

    Article  CAS  Google Scholar 

  13. Chang, D. W., Claassen, G. F., Hann, S. R. & Cole, M. D. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell. Biol. 20, 4309–4319 (2000)

    Article  CAS  Google Scholar 

  14. Sears, R. C. The life cycle of c-Myc: from synthesis to degradation. Cell Cycle 3, 1133–1137 (2004)

    Article  CAS  Google Scholar 

  15. Frykberg, L., Graf, T. & Vennstrom, B. The transforming activity of the chicken c-myc gene can be potentiated by mutations. Oncogene 1, 415–422 (1987)

    CAS  PubMed  Google Scholar 

  16. Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nature Cell Biol. 6, 308–318 (2004)

    Article  CAS  Google Scholar 

  17. Rabbitts, T. H., Hamlyn, P. H. & Baer, R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 306, 760–765 (1983)

    Article  ADS  CAS  Google Scholar 

  18. Bemark, M. & Neuberger, M. S. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line. Oncogene 19, 3404–3410 (2000)

    Article  CAS  Google Scholar 

  19. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985)

    Article  ADS  CAS  Google Scholar 

  20. Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128 (1992)

    Article  CAS  Google Scholar 

  21. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003)

    Article  CAS  Google Scholar 

  22. Maclean, K. H., Keller, U. B., Rodriguez-Galindo, C., Nilsson, J. A. & Cleveland, J. L. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol. Cell. Biol. 23, 7256–7270 (2003)

    Article  CAS  Google Scholar 

  23. Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002)

    Article  ADS  CAS  Google Scholar 

  24. Egle, A., Harris, A. W., Bouillet, P. & Cory, S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA 101, 6164–6169 (2004)

    Article  ADS  CAS  Google Scholar 

  25. O'Connor, L. et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17, 384–395 (1998)

    Article  CAS  Google Scholar 

  26. Schmitt, C. A. et al. Dissecting p53 tumour suppressor functions in vivo. Cancer Cell 1, 289–298 (2002)

    Article  CAS  Google Scholar 

  27. Gaidano, G. et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 88, 5413–5417 (1991)

    Article  ADS  CAS  Google Scholar 

  28. Bhatia, K. G., Gutierrez, M. I., Huppi, K., Siwarski, D. & Magrath, I. T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 52, 4273–4276 (1992)

    CAS  PubMed  Google Scholar 

  29. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997)

    Article  CAS  Google Scholar 

  30. Yu, D. & Thomas-Tikhonenko, A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21, 1922–1927 (2002)

    Article  CAS  Google Scholar 

Download references


We thank M. S. Jiao, C. Rosenthal, M. Yang, S. Ray, C. Yang and I. Linkov for technical assistance and J. Zilfou, R. Dickins, E. Cepero, M. Spector, J. Fridman and other members of the Lowe laboratory for advice and/or critical reading of the manuscript. We also thank A. Hunt and G. Evan for helpful advice, and T. Mak and A. Strasser for mice. This work was supported by a postdoctoral fellowship from the Helen Hay Whitney Foundation (M.T.H.), an NCI postdoctoral training grant (A.B.), a program project grant from the National Cancer Institute (W.P.T and S.W.L.) and a grant from the Irving Hansen Memorial Foundation (W.P.T). W.P.T. is a Leukemia and Lymphoma Society Scholar and S.W.L. is an AACR-NCRF Research Professor.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Scott W. Lowe.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Figure 1

This figure shows a diagram of the adoptive transfer strategy, as well as diagrams of the retroviral vectors used. (Canvas image, 248KB) (PDF 90 kb)

Supplementary Figure 2

This figure shows immunohistochemistry staining of lymphoma cells. It also shows GFP histograms of cells before and after stem cell reconstitution. (Canvas image, 1.3MB) (PDF 237 kb)

Supplementary Figure 3

This figure shows western blot analysis of FL5.12 pre-B cells. It also shows PCR analysis of DJ recombination to assess tumor clonality. (Canvas image, 1.4MB) (PDF 702 kb)

Supplementary Table

A table showing the p53 and MYC status of 31 Burkitt lymphomas. (MS Word file, 12KB) (RTF 8 kb)

Supplementary Figure Legend

A file containing figure legends for the Supplementary Figures. (MS Word file, 8KB) (RTF 6 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hemann, M., Bric, A., Teruya-Feldstein, J. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807–811 (2005).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing